PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-37.55%
Negative net income growth while CRVO stands at 48.37%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
14.84%
D&A growth of 14.84% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
No Data
No Data available this quarter, please select a different quarter.
0.81%
Less SBC growth vs. CRVO's 55.52%, indicating lower equity issuance. David Dodd would confirm the firm still retains key staff.
106.29%
Well above CRVO's 37.83% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
81.80%
Growth well above CRVO's 111.06%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
No Data
No Data available this quarter, please select a different quarter.
9.51%
Operating cash flow growth below 50% of CRVO's 46.74%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
38.16%
CapEx growth of 38.16% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.16%
We have mild expansions while CRVO is negative at -68.42%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
No Data
No Data available this quarter, please select a different quarter.
1171.17%
Issuance growth of 1171.17% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.